Dental Corporation to move from mai to SET on October 1

Dental Corporation Public Company Limited, or D, is maintaining its target for total revenue growth in 2026 at around 10%. Chief Executive Officer Pornsak Tantapakul said foreign customers account for the main share, roughly 60-70% of total revenue, and their purchasing power remains strong with growth of nearly 10%. Thai customers account for about 30% of total revenue and have contracted by around 3-4% amid the economic slowdown. Growth in foreign customers has helped offset the slowdown in the domestic market. For the fourth quarter of 2026, the company expects operating results to continue growing on the back of foreign customers' purchasing power, and it will begin considering opening new branches again, focusing on locations that target foreign customers. Initially, it plans to open an average of about one branch per quarter. The company is continuing to pursue growth after meeting all the qualifications to move from the Market for Alternative Investment, or mai, to trade on the Stock Exchange of Thailand, or SET, which will help raise its profile, build confidence, and open up more opportunities to reach institutional investors. After listing on the SET, several securities firms have begun preparing analyst reports assessing its growth prospects over the next one to two years. Meanwhile, the major shareholder group, which holds about 50% of the shares, has no plans to sell its shares and does not intend to raise capital at this time. The company has a strong cash flow position and a policy of paying dividends every six months, representing a dividend yield of about 5-6% per year.

SpyGlass Pharma, Inc. announced today it has acquired all outstanding shares of common stock of Advanced Vision Science, Inc., an ophthalmic medical device company and manufacturer of intraocular lenses and lens materials, for approximately $13 million in cash. AVS was a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd. and is the current supplier of the intraocular lens used in SpyGlass Pharma's two Phase 3 registrational trials evaluating the BIM-IOL System. The acquisition secures scalable commercial intraocular lens manufacturing capacity for SpyGlass Pharma's lead product candidate and accelerates its pathway to adding premium lens options into its intraocular-lens-based drug delivery system. Under the agreement, AVS will be the exclusive manufacturer and supplier of several types of intraocular lenses to Santen for commercialization in Japan, and will continue to license its glistening-free hydrophobic acrylic lens material to Bausch + Lomb for use in the enVista intraocular lens line and manufacture products for other global intraocular lens companies. SpyGlass Pharma said it intends to continue supporting AVS customers and licensees utilizing their proprietary intraocular lens material technology, such as Santen, Bausch + Lomb, and other global intraocular lens companies.

Neuromod Devices has announced the appointment of Joe Ghiz as Chief Commercial Officer and Shannon Basham as VP of Channel Development. Ghiz joins Neuromod's senior management team and will lead the company's global commercial function as it continues to strengthen its position as the category creator in tinnitus care, with CEO Dr. Ross O'Neill citing robust clinical evidence, global regulatory approval, and broad commercial adoption as positioning the company for rapid scaling to address the needs of 740 million tinnitus sufferers worldwide. Ghiz joins from Align Technology, the company behind Invisalign, where he helped create and scale the clear aligner category and built a $10 billion company, and previously spent over a decade at Johnson & Johnson Vision Care in leadership roles spanning sales, marketing, and business development. Basham brings more than 20 years of experience in the hearing care industry, having most recently served as Senior Director of Audiology for Sonova Group in the United States of America, where she was the market-facing head of audiology for the Phonak and Unitron wholesale businesses. The appointments support Neuromod's goal of positioning its non-invasive bimodal neuromodulation tinnitus treatment device, Lenire, as a new standard of care in ENT and audiology practices.

Bernstein has named Sonova as its short-term top pick and Alcon as its preferred long-term idea in a new H2 playbook for European medtech, assigning both "outperform" ratings with price targets of CHF 275 and CHF 76.15, respectively. Sonova, the world's No. 1 player in the $7.7 billion hearing aid wholesale market with roughly a 25% unit share, is expected to benefit from a multi-pronged growth setup into its H1 2026/27E results in November, with Bernstein forecasting H1 wholesale organic growth of 10.1% versus consensus at 8% and Group organic growth of 6.5% versus consensus of 4.9%. The bull case rests on continued strength from the EON Sphere launch, further share gains at Costco, where the Infinio-based device only entered the channel in March 2026, and another seven months of tailwind from Virto R hearing aid sales, plus a sharp H2 improvement in the Cochlear Implant business and accelerating M&A contribution in Retail as rivals Demant and Amplifon remain financially constrained. Bernstein's core EBIT estimates sit 5-8% above consensus across 2026/27E-2028/29E. On Alcon, the dominant ophthalmology player holding #1 or #2 positions across most of its sub-markets, Bernstein argues investor sentiment on the intraocular lens and consumables businesses has become "overly negative" and that the pressure is "largely transitory," expecting implantables growth to accelerate to 4% in 2027. Bernstein's constant-currency revenue growth estimates run 38-112 bps above consensus for 2026E-2028E, with core EPS estimates 1-9% higher, and at roughly 17x NTM P/E it sees an attractive entry point into what it calls a "multi-year compounding business."